GlassScriptPhysician profile
Steven M Rosner
NPI 1669441929
$2,821.61
in general payments reported to CMS, 2019-2025
25 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $37.06 · 2021: $230 · 2022: $385 · 2023: $665 · 2024: $569 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $723.44 | 2019-2025 | Enbrel, Evenity, Prolia |
| Abbvie INC. | $551.70 | 2019-2025 | Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $482.87 | 2019-2025 | |
| Pfizer INC. | $213.18 | 2019-2024 | |
| Glaxosmithkline, LLC. | $181.52 | 2019-2023 | Benlysta |
| Genzyme Corporation | $102.24 | 2019-2025 | |
| Janssen Biotech, INC. | $97.43 | 2019-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.26 | 2023-2024 | Cyltezo |
| Sandoz INC. | $52.96 | 2023-2025 | Hyrimoz, Jubbonti |
| Fresenius Kabi USA, LLC | $45.87 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $45.78 | 2022 | |
| Lilly USA, LLC | $34.38 | 2023-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $33.41 | 2021-2025 | |
| Depuy Synthes Sales INC. | $25.78 | 2021 | |
| Bioventus LLC | $20.86 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Novo Nordisk INC | $19.28 | 2025 | Wegovy |
| Tonix Medicines, INC. | $17.87 | 2025 | Tonmya |
| Organon LLC | $15.69 | 2023 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $15.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2023 | Entyvio |
| Merck Sharp & Dohme LLC | $12.77 | 2022 | |
| Shire North American Group INC | $12.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.